Stock Events

Stock Events

Atossa Therapeutics 

€6.75
314
-€1.04-13.29% Friday 17:26

Statistics

Day High
0.49
Day Low
0.49
52W High
1.08
52W Low
0.45
Volume
-
Avg. Volume
-
Mkt Cap
871.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.19
-0.81
-0.42
-0.04
Expected EPS
-0.99
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-48.35MNet Income

Analyst Ratings

18.59Average Price Target
The highest estimate is 18.97.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow YAG2.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap153.59B
Pfizer is involved in developing treatments in various therapeutic areas, including those Atossa is targeting, making them direct competitors in the pharmaceutical space.
Merck
MRK
Mkt Cap276.38B
Merck operates in similar therapeutic areas as Atossa, including breast cancer treatments, positioning them as competitors.
Novartis
NVS
Mkt Cap280.79B
Novartis competes with Atossa in the oncology sector, particularly in developing treatments for breast cancer.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences focuses on innovative therapies, including for cancer, directly competing with Atossa's therapeutic development efforts.
AMGEN
AMGN
Mkt Cap185.74B
Amgen's focus on biologics and treatments for serious illnesses places them in competition with Atossa, especially in cancer therapy.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie's work in oncology and focus on innovative treatments make them a competitor to Atossa in the pharmaceutical and biotech industry.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca's extensive research in oncology, including breast cancer, positions them as a competitor to Atossa.
Bristol-Myers Squibb
BMY
Mkt Cap119.87B
Bristol Myers Squibb's involvement in cancer research and development of oncology treatments competes with Atossa's focus areas.
Lilly(Eli) &
LLY
Mkt Cap789.69B
Eli Lilly's commitment to cancer research, including breast cancer, makes them a direct competitor to Atossa in the pharmaceutical industry.

About

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Show more...
CEO
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Employees
15
Country
United States
ISIN
US04962H5063
WKN
000A2JJ99

Listings

STU
DE
YAG.STU
MU
DE
YAG.MU
BOATS
BOATS
ATOS.BOATS
MX
MX
ATOS.MX

0 Comments

Share your thoughts

FAQ

What is Atossa Therapeutics stock price today?▼
The current price of YAG2.F is €6.75 EUR — it has decreased by -13.29% in the past 24 hours. Watch Atossa Therapeutics stock price performance more closely on the chart.
What is Atossa Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Atossa Therapeutics stocks are traded under the ticker YAG2.F.
Is Atossa Therapeutics stock price growing?▼
YAG2.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Atossa Therapeutics has showed a -32.23% decrease.
What is Atossa Therapeutics market cap?▼
Today Atossa Therapeutics has the market capitalization of 871.9M
What is Atossa Therapeutics revenue for the last year?▼
Atossa Therapeutics revenue for the last year amounts to 0 EUR.
What is Atossa Therapeutics net income for the last year?▼
YAG2.F net income for the last year is -48.35M EUR.
How many employees does Atossa Therapeutics have?▼
As of April 29, 2026, the company has 15 employees.
In which sector is Atossa Therapeutics located?▼
Atossa Therapeutics operates in the Health & Wellness sector.
When did Atossa Therapeutics complete a stock split?▼
The last stock split for Atossa Therapeutics was on February 02, 2026 with a ratio of 1:15.
Where is Atossa Therapeutics headquartered?▼
Atossa Therapeutics is headquartered in Seattle, United States.